Frontier Pharma : Pain Treatment Teeming Market

Frontier Pharma : Pain Treatment Teeming Market
Due to the diverse nature of its target, pain treatment warrants a wide range of options. The
multitude of analgesics available today and the several delivery methods devised for the best
patient care signify the growth and importance of the pain treatment market.
Pain management and treatment deals with different levels of pain and over the years, options
such as pharmacotherapy, radiation, or physical therapy, or surgery have been used to treat pain.
Innovation is the key to the pain treatment market and companies have been consistently
developing new and effective drugs to treat mild to severe pain.
The active pipeline of pain treatment and management presently holds more than 790 products at
different stages of development. Competition in the market is tough and even with the fact that the
pain treatment market is considerably mature, the truth is that science and medicine can never give
up on innovation. Developing new therapies that are less toxic, less addictive, and more efficacious
than existing medications is the challenge that players in this market have to focus on to stay
strong in the competition.
The significance of first-in-class drugs for pain treatment is vital and presents increasing
investment opportunities for drug manufacturing companies. The pain treatment market, in general,
has witnessed a lot of activity over the past eight years, with 261 licensing deals and about 112 codevelopment
deals. However, when it comes to first-in-class product deals, the market has been
relatively slow.
First-in-class, as the US FDA suggests, are drugs that use a novel and unique method of action to
treat a medical condition. A first-in-class drug spells innovation and, though rewarding, can be
extremely risky and time-consuming. However, drug companies are willing to take this risk of
investment. Around 170 first-in-class products in the pain treatment market are available for codevelopment
and licensing deals. Some of these products have been showcased in preclinical
trials and have proven to provide high rewards for investments.
Browse the full Global Pain Treatment Market report at http://www.mrrse.com/frontier-pharmapain
Studies by MRRSE Research show that the market for pain treatment is dominated by steroidal
anti-inflammatory drugs and opioids and the presence of novel products has been unable to
challenge this dominance. In 2008, the number of patent applications for novel pain therapeutics
was 4,970, which dropped to 3,492 in 2012, presenting an average annual decline of 8%. This
signifies the unmet therapeutic needs when it comes to new methods of pain treatment. However,
this can be addressed by technological advances and dedicated research efforts.
As mentioned earlier, the active pipeline of pain treatment presently holds about 796 products at
various phases of development presenting an increased diversity of molecular targets. The 122
first-in-class projects in active development stage form 13.6% of the overall pipeline, of which 65
first-in-class molecular targets reflect an increased level of innovation.

Big Pharma companies such as Novartis, Boehringer Ingelheim, Sanofi, Allergan, and Merck & Co.
are reportedly driving the pain treatment and therapeutics market in the segment of innovation.
Merck led the market between 2008 in terms of patent grants, with 59 out of 142 patent
applications being granted. Boehringer Ingelheim was granted 35, Allergan received 34, while
Novartis and Sanofi received 30 each.
The pain treatment and management market is largely fragmented and this poses an opportunity
for new classes of drugs as numerous blockbuster patents near expiration.
Table of Contents
1 Table of Contents
1.1 List of Figures
2 Executive Summary
2.1 Large and Innovative Pipeline
2.2 Highly Diversified Range of Innovative Programs in Early Pipeline and in Granted Patents
2.3 Active Deals landscape with Numerous Investment Oppertunities
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Development Remains Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 MRRSE Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.1.1 Chronic and Neuropathic Pain
4.1.2 Disease Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment Option
4.1.5 Treatment Algorithm

4.2 Overview of Marketed Products for Pain
4.2.1 Analgesic Product Categories
4.2.2 Molecular Type Analysis
4.2.3 Molecular Target Analysis
4.2.4 Current Unmet Needs
Send An Enquiry : http://www.mrrse.com/enquiry/108
5 Assessment of Pipeline Product Innovation
5.1 Pain Pipeline by Molecule Type, Phase and Therapeutic Targets
5.2 Comparative Distribution of Programs between the Pain Market and Pipeline by Therapeutic
Target Family
5.3 First-in-Class Pipeline Programs
5.4 First-in-Class Targets by Pain Subtype
6 Pain Patent Analysis
7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Fatty Acid Amide Hydrolase
7.2 Pipeline Programs Targeting Purinoceptor 3
7.3 Pipeline Programs Targeting Purinoceptor 7
7.4 Pipeline Programs Targeting Purinoceptor 4
7.5 Pipeline Programs Targeting Orexin Receptor Type 1
7.6 Pipeline Programs Targeting Neuronal Nitric Oxide Synthase
7.7 Pipeline Programs that Target Tropomyosin-Related Kinase A
7.8 Pipeline Programs that Target C-C Chemokine Receptor 2
7.9 Pipeline Programs that Target Endomorphin 2
7.10 Pipeline Programs that Target Protein Kinase C?
7.11 Pipeline Programs that Target Opioid Receptor-Like-1 Receptor
7.12 Pipeline Programs that Target Bradykinin B1 Receptor
7.13 Pipeline Programs Targeting Galanin Receptor 2
7.14 Pipeline Programs Targeting Nerve Growth Factor

8 Deals and Strategic Consolidations
8.1 Industry Industry-wide First-in-Class Deals
8.2 Pain Deals Landscape
8.3 Licensing Deals
8.3.1 Molecule Type
8.3.2 Mechanism of Action
8.4 Co-development Deals
8.4.1 Molecule Type
8.4.2 Mechanism of Action
8.5 First-in-Class Programs Not Involved in Licensing or Co-Development Deals
9 Appendix
9.1 Abbreviations
9.2 References
9.3 Contact Us
9.4 Disclaimer
Upcoming Report :
Salt Market - Global Industry Expert Opinions Analysis, Emerging Opportunities,
Market Size, Share, Growth Drivers, Market Trends, Statistics And Forecast 2015 –
2020 http://www.mrrse.com/salt-market
Global salt production has increased in 2013 after a decline in 2011 and 2012. The rise is
attributed to reviving demand from the road de-icing and chlor-alkali markets on account of
economic recovery in the U.S. and Europe.
Demand from the chemical sector, especially chlor-alkali and soda ash industries, is expected to
drive the salt market. Additionally, winter demand from road de-icing market is another significant
driver for salt market. However, salt is a volatile material and the difficulty in transportation might
offset the market growth. New applications from the chemical sector are expected to bring demand
prospects for salt market.

Phosphate Minerals Market - Global Industry Expert Opinions Analysis, Emerging
Opportunities, Market Size, Share, Growth Drivers, Market Trends, Statistics And
Forecast 2015 – 2020 http://www.mrrse.com/phosphate-minerals-market
Phosphate minerals are minerals containing tetrahedrally co-ordinated anions. The phosphate
group of minerals includes triphylite, monazite, pyromorphite, vanadinite, erythrite, lazulite,
turquoise, autunite, carnotite apatite group, etc. Phosphate minerals of apatite group are generally
mined from phosphate rocks. Main apatite mineral types include, Collophane, Francolite, and
Dahlite. Other phosphate bearing minerals of economic significance are monazite, turquoise, and
pyromorphite. Phosphate deposits are classified in three main types namely, marine sedimentary
phosphorite, apatite-rich igneous rocks and guano accumulations. Agriculture is the largest enduser
industry of phosphate minerals. Phosphate minerals are also used in food preservatives,
animal feed, cosmetics, fungicides, ceramics, metallurgy and water treatment. Production of
fertilizers is the major application for phosphate containing minerals. Phosphate minerals are
generally mined by surface mining. After removal of ore from the ground the second stage of
mining is the beneficiation process where the ore is separated by using various chemicals reagents
in order to extract pure minerals.
About Us
Market Research Reports Search Engine (MRRSE) is an industry-leading database of market
intelligence reports. Headquartered in New York, U.S., MRRSE is driven by a stellar team of
research experts and advisors trained to offer objective advice. Our sophisticated search algorithm
returns results based on the report title, geographical region, publisher, or other keywords.
MRRSE partners exclusively with leading global publishers to provide clients single-point access to
top-of-the-line market research. MRRSE’s repository is updated every day to keep its clients ahead
of the next new trend in market research, be it competitive intelligence, product or service trends or
strategic consulting.
Contact Us:
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207

United States
Tel: +1-518-618-1030
Email: sales@mrrse.com
Website: http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/